Why Unit Price Is the Wrong Number
The leukopak invoice says one thing. The actual cost of running your experiment says something different. The gap between those two numbers is where most procurement decisions quietly go wrong.
Unit price — the cost per leukopak, per mL of apheresis product, per vial of PBMCs — measures what you pay before you know whether the cells will work. It doesn’t account for the experiment that failed because post-thaw viability came in low. It doesn’t account for the repeat purchase when a collection arrived outside spec. It doesn’t account for the staff hours spent troubleshooting a protocol that worked fine with the last supplier’s material and broke with the new one.
This piece builds the full cost model. Four supplier tiers, real math at each level, and the variables that determine where your actual cost lands within each tier.
The Four Supplier Tiers
The leukopak and PBMC supplier market stratifies into four tiers based on what’s included in the price.
Tier 1: Basic catalog
Cryopreserved PBMCs or leukopaks from a general research biospecimen supplier. Minimal donor characterization, standard collection infrastructure, no GMP option, no disease-state access beyond a basic healthy donor pool. These products are optimized for cost, not for consistency or clinical application. Post-thaw viability specs are often stated as minimums (typically “≥70% viable”) with no performance data behind them.
Typical unit cost range: $150–$400 per leukopak equivalent, depending on volume.
Tier 2: Mid-market characterized
Characterized healthy donor leukopaks with documented subset data (T cell, B cell, NK, monocyte percentages), consistent processing protocols, and some disease-state access. GMP may be offered but is not the primary business. Post-thaw viability specs are typically “≥80% viable” with more consistent performance behind them.
Typical unit cost range: $400–$800 per leukopak.
Tier 3: Premium clinical-grade
Full donor characterization including KIR genotyping, HLA typing, and clinical annotation for disease-state donors. Dedicated GMP infrastructure. Tight processing timelines for fresh material. RUO-to-GMP continuity from the same donor pool. Post-thaw viability data from documented collections rather than specification minimums.
Typical unit cost range: $800–$1,500 per leukopak, varying by donor type, characterization level, and fresh vs. cryopreserved.
Tier 4: Same-day fresh, CTDMO-integrated
Same-day processing after apheresis collection, 30-minute receipt-to-first-spin window, owned processing infrastructure (not third-party). GMP-compliant from collection through processing. Integrated with CTDMO manufacturing workflows. Full donor continuity from RUO through IND.
Typical unit cost range: $1,000–$2,000+ per collection, depending on donor type and GMP requirements.
The Full Cost Model
Each tier’s unit price is the starting point, not the final number. Five variables determine where your actual cost lands.
Variable 1: Post-thaw recovery rate
A Tier 1 product priced at $200 that comes in at 70% post-thaw viability costs more per usable cell than a Tier 3 product priced at $900 that comes in at 90%. The math:
- Tier 1: $200 / 0.70 recovery = $286 per unit of usable cells
- Tier 3: $900 / 0.90 recovery = $1,000 per unit of usable cells
Tier 1 is still cheaper per usable cell in this example. But that calculation assumes the first purchase produces usable cells. It doesn’t account for what happens when a lot fails your minimum viability threshold and you have to reorder.
Variable 2: Lot failure rate
Most labs track average viability. Few track lot failure rate — the percentage of orders that come in below the threshold required to run the experiment. Tier 1 suppliers with ≥70% viability specs produce more lots that land at 68%, 65%, 71%. Every failed lot means a repeat purchase at full price, plus lost time while waiting for the replacement.
At a 10% lot failure rate (conservative for Tier 1), you’re effectively paying 110% of unit price for the cells you actually use. At a 20% failure rate, you’re paying 125%. A Tier 3 supplier with a 2–3% lot failure rate is paying 102–103%.
Variable 3: Staff time per failed experiment
A failed experiment doesn’t just cost the cells. It costs researcher time to diagnose the failure, troubleshoot the protocol, and rerun the assay. In a research lab where scientist time runs $50–$150/hour loaded, a single failed experiment with 4–6 hours of diagnostic work adds $200–$900 to the effective cell cost. At 10 failed experiments per year from inconsistent material, that’s $2,000–$9,000 in staff cost that never shows up on the procurement line item.
Variable 4: Processing overhead for cryopreserved material
Cryopreserved cells require a thaw and wash step before use. For experienced labs, this is 30–60 minutes of technician time. For labs less familiar with the protocol, it’s a source of additional variability. The cost is real even when it’s small.
Fresh cells don’t require this step. If you’re running multiple experiments per week with fresh material, the cumulative time savings are material.
Variable 5: Repeat experiment cost for downstream failures
The most expensive failure mode is one that doesn’t surface at the PBMC stage — it surfaces downstream. You ran your CAR-T manufacturing process, the transduction efficiency was low, and you don’t know if it was the vector, the protocol, or the starting material. You spend 2 weeks troubleshooting before deciding the starting material was the variable. That failure cost isn’t $900 for a leukopak. It’s $20,000–$100,000 in manufacturing time, vector costs, and timeline delay.
This is the failure mode that clinical-stage programs optimize against when they pay Tier 4 prices for well-characterized, consistently processed starting material. The unit price premium buys consistency insurance.
The Full Cost Comparison Across Four Tiers
| Cost Variable | Tier 1 (Basic) | Tier 2 (Mid-market) | Tier 3 (Premium) | Tier 4 (Same-day fresh) |
|---|---|---|---|---|
| Unit price (leukopak equiv.) | $150–$400 | $400–$800 | $800–$1,500 | $1,000–$2,000+ |
| Post-thaw viability spec | ≥70% | ≥80% | ≥85–90% | N/A (fresh, no thaw) |
| Estimated lot failure rate | 10–20% | 5–10% | 2–5% | <2% |
| Monocyte recovery | Variable | Moderate | Good (cryo); Full (fresh) | Full (fresh, same-day) |
| NK cell functional recovery | Low–moderate | Moderate | Good | Highest (fresh) |
| Effective unit cost (adjusted for failures) | $165–$500 | $420–$880 | $820–$1,575 | $1,020–$2,040 |
| Downstream failure risk | High | Moderate | Low | Lowest |
| GMP-eligible | No | Limited | Yes | Yes |
When Each Tier Makes Sense
Tier 1 makes sense for early discovery work where protocol optimization matters more than cell consistency, where the assay doesn’t depend on monocytes or NK cells, and where the lab has tolerance for repeat experiments without timeline consequences. It doesn’t make sense for any application with downstream cost amplification — manufacturing processes, IND-enabling studies, or assays with long run times.
Tier 2 is the workhorse for established research labs running T cell-heavy assays at moderate throughput. The consistency improvement over Tier 1 is significant at equivalent volume; the price premium pays back in reduced failure rate within a few quarters.
Tier 3 makes sense when the application requires full subset characterization, disease-state donors, or GMP traceability. The unit price premium is real, but the failure rate reduction and functional fitness improvement change the effective cost calculation at any meaningful experimental volume.
Tier 4 makes sense for clinical manufacturing programs, IND-enabling studies with tight timelines, and any application where monocyte or NK cell integrity is non-negotiable. The premium isn’t paying for brand — it’s paying for the elimination of a failure mode that costs more than the unit price difference every time it occurs.
How OrganaBio Fits the Model
OrganaBio operates at Tier 3 and Tier 4 depending on the application. Fresh leukopaks with OrganaBio’s 30-minute receipt-to-first-spin processing are Tier 4 for same-day applications. Cryopreserved product from the same donor pool at the same processing standard is Tier 3.
The spec data across 2,500+ clinical samples: less than 3% granulocyte/red cell contamination, 85% average PBMC yield, and post-thaw viability above 80% for the cryopreserved fraction. These are averages from documented collections, not specification minimums.
For CTDMO and GMP manufacturing programs, the RUO-to-GMP donor continuity model eliminates one of the hidden costs entirely: the comparability work required when research and clinical phases use material from different supplier pools. That transition cost can run $50,000–$500,000 in comparability study time and regulatory documentation. Staying on the same donor pool from discovery through IND avoids it.
Contact OrganaBio’s scientific team to discuss your program’s volume requirements and what the full cost model looks like for your specific application.
Source from OrganaBio
FDA-registered. ISO 7 cGMP. Ships anywhere in the US.
Request a QuoteView ProductsFrequently Asked Questions
What is ‘cost per usable cell’ and why does it give a better picture than sticker price per leukopak?
Cost per usable cell is the total cost of starting material divided by the number of cells that meet your specifications after processing, not the total cell count on the label. A leukopak at $3,000 with 30% granulocyte contamination and 75% post-isolation viability delivers far fewer usable cells than a leukopak at $4,500 with 2% granulocyte contamination and 92% post-isolation viability. The math: if your protocol requires 500 million viable PBMCs with less than 3% granulocyte contamination, and a cheaper lot fails that threshold, the cost of that lot is effectively infinite — you cannot use it. Sticker price is the wrong denominator. Usable cells per dollar is the denominator that maps to your manufacturing economics.
What parameters most directly drive PBMC yield from a leukopak?
The three parameters with the most direct effect on PBMC yield are: total white blood cell count in the leukopak, granulocyte percentage, and time from collection to first processing step. Higher total WBC increases raw input. Lower granulocyte percentage means more of those WBCs are mononuclear cells that will be recovered in the PBMC fraction. Shorter time to first spin means less granulocyte-mediated degradation of neighboring lymphocytes before the density gradient removes them. A leukopak with 8 billion WBCs, 15% granulocytes, and a 20-hour hold time may yield fewer usable PBMCs than a leukopak with 5 billion WBCs, 2% granulocytes, and a 30-minute receipt-to-first-spin — because in the second case, the input cells are in better condition when isolation begins.
What are the four cost tiers in the leukopak market and what tradeoffs does each represent?
A rough market segmentation: Tier 1 — academic blood banks and regional collection centers. Lowest sticker price, minimal COA data, no GMP documentation, highly variable granulocyte contamination, long receipt-to-processing gaps. Tier 2 — mid-market research-grade suppliers. Moderate pricing, standard COA (viability and cell count), limited T cell subset data, centralized processing with overnight transport. Tier 3 — GMP-compliant centralized labs. Higher pricing, GMP COA with subset data and infectious disease screening, but centralized model means overnight transport from remote collections. Tier 4 — dedicated CTDMO with co-located CPC infrastructure. Highest unit cost, GMP COA with full documentation package, receipt-to-first-spin under 30 minutes, CTDMO manufacturing scope. For programs where starting material quality directly determines manufacturing success rate, the total cost of Tier 4 is often lower than Tier 2 or Tier 3 when you factor in lot rejection rates and failed runs.
How do I calculate the cost impact of granulocyte contamination on my manufacturing budget?
Calculate what percentage of your lots fail your granulocyte specification threshold. If you require ≤3% granulocyte contamination and your current supplier’s lots come in at 5-8%, you have two cost drivers: direct lot rejection (you paid for material you cannot use) and indirect damage (granulocyte protease activity that degraded T cells in lots you did accept but that performed below expectation). Quantify the rejection rate as (rejected lots / total lots ordered) × unit cost per lot. For the indirect damage, look at your manufacturing success rate by lot — if lots with 4% granulocytes consistently produce lower final product yield than lots with 1%, that differential yield loss is a hidden cost per run that gets buried in ‘natural process variability.’ Tracking starting material parameters against manufacturing outcomes makes this cost visible.
What does a true total cost of goods analysis look like for starting material across a Phase I CAR-T program?
A Phase I program manufacturing 6-12 autologous patient lots needs to account for: unit cost per leukopak × lots ordered (including anticipated rejects), failed manufacturing run rate × average cost of a failed run (labor, consumables, facility time), comparability study cost when switching suppliers or lot grades, supplier qualification and audit cost (amortized over program duration), and opportunity cost of lot-to-lot variability on batch release timelines. A single failed manufacturing run in a Phase I autologous program can cost $50,000-$150,000 in direct costs and potentially delay the clinical program by weeks if a replacement lot requires re-qualification. The cost calculation that drives supplier selection decisions should start with the cost of a failed run, not the cost of a leukopak.
